https://www.selleckchem.com/pr....oducts/tocilizumab.h
5%) died by 28 days after diagnosis. Specific underlying comorbidities (age 65 [aOR 3.0, 95%CI 1.7-5.5, p0.001], congestive heart failure [aOR 3.2, 95%CI 1.4-7.0, p=0.004], chronic lung disease [aOR 2.5, 95%CI 1.2-5.2, p=0.018], obesity [aOR 1.9, 95% CI 1.0-3.4, p=0.039]) and presenting findings (lymphopenia [aOR 1.9, 95%CI 1.1-3.5, p=0.033], abnormal chest imaging [aOR 2.9, 95%CI 1.1-7.5, p=0.027]) were independently associated with mortality. Multiple measures of immunosuppression intensity were not associated with mortali
Like
Comment
Share
